S100A9 and amyloidosis: The main goal of this research is to demonstrate that S100A9, in addition to commonly perceived Aβ peptide, may be a leading causative component of the amyloid-neuroinflammatory cascade, triggered in TBI and presenting the risk for AD and other neurodegeneration disease development.